Humanoid, Inc (HERB) Fair Value & Analysis
Consumer Defensive · US · Market cap $4.9M
Humanoid, Inc
HERB · US
Fair value as of: Jul 29, 2026
From 17 valuation models · updated 12 days ago
Fair value updated Jul 29, 2026, revised from $0.0288 to $0.0178 (−38.3%) since Jun 26, 2026. Share price +21.4% over the past month.
A solid business, but screening 15% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0180). The favourable scenario is already priced in.
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
- The models converge in a tight band ($0.0169 to $0.0180), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.
How to read this chart
60‑month range $0.0160 – $0.2590 · fair‑value band $0.0169 – $0.0180 · the $0.0210 price screens above the $0.0178 fair value. Dashed = 300-day average. As of Jul 29, 2026.
Analysis
Humanoid, Inc (HERB) currently trades at $0.0210, while our model-based Fair Value estimate is $0.0178, implying the stock looks roughly 15.2% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Humanoid, Inc generated revenue of $24.1M at a net margin of 33.4%. Revenue declined 24.5% year over year. It earns a return on equity of 2.9%. The balance sheet holds a net cash position of $8.3M. Fundamentals as of Jul 29, 2026
Our scenario range runs from $0.0169 (bear case) to $0.0180 (bull case); at $0.0210, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 67% below its 52-week high and 54% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at 102% fair-value upside, at -15%, HERB screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Asset-Based ($1.21) versus DCF Models ($0.1900). Highest evidence: Rev-Margin DCF (74).
Notify me when HERB reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 4
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Humanoid, Inc., through its subsidiaries, designs, develops, manufactures, and markets farming and sideline products; chemical materials and products; textiles; construction materials; and livestock and poultry products.
Full company description
Humanoid, Inc., through its subsidiaries, designs, develops, manufactures, and markets farming and sideline products; chemical materials and products; textiles; construction materials; and livestock and poultry products. It cultivates, processes, markets, and distributes various food and agro-byproducts; and manufactures and supplies nutrition and healthcare products. The company's products portfolio includes cotton and wool, sorghum, grains, barley, soybean, alfalfa, corn, and wheat; onions, beets, lupin, bell peppers, potato, peas, carrots, and brussels potato; fuji apple, wolf berry, water melons, apricots, hami melons, peaches, chinese pear, tomato, grapes, dates, yellow river melons, and medlar; hops, nursery crops, liquorices root, flaxseed, aloe plant, TCM herbs, and ginseng; oil seeds, black melon, sunflower, corn; and chicken, pigs, sheep, eggs, and cows. In addition, it produces drip irrigation equipment, fertilizers, and animal feeds; and engages in the acquisition and development of gold, silver, and other mineral properties. The company operates in the United States, the People's Republic of China, and the Philippines. Humanoid, Inc. also exports its products. The company was formerly known as YaSheng Group and changed its name to Humanoid, Inc. in April 2024. The company was founded in 1998 and is headquartered in Sunnyvale, California. Humanoid, Inc. is a subsidiary of Gansu Yasheng Salt Chemical Industrial Group, Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Humanoid, Inc reported revenue of $24.1M in FY2024 versus $12.5M in FY2020, a compound +17.8%/yr. Reported net income was $8.1M in FY2024, compounding +28.2%/yr from FY2020.
of which total revenue −36.1 pp · buybacks/dilution −0.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
HERB screens 15% overvalued. Compare with Muyuan Foods Group →
Peer Group
Farm Products · 288 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Farm Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Farm Products stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Muyuan Foods Group 002714 | ¥40.90 | ¥48.19 | +18% |
| Wens Foodstuff Group 300498 | ¥14.51 | ¥12.08 | -17% |
| Mowi ASA MOWI | kr 188.40 | kr 262.59 | +39% |
| PT Charoen Pokphand Indonesia Tbk, CPIN | 3,120 IDR | 7,076 IDR | +127% |
| Charoen Pokphand Foods Public Company CPF | 22.00 THB | 55.71 THB | +153% |
| PT Triputra Agro Persada Tbk TAPG | 1,540 IDR | 3,105 IDR | +102% |
| PT FAP Agri Tbk FAPA | 7,300 IDR | 7,463 IDR | +2% |
| PT Japfa Comfeed Indonesia Tbk JPFA | 2,070 IDR | 7,231 IDR | +249% |
| Thaifoods Group TFGR | 10.60 THB | 23.53 THB | +122% |
| PT Jhonlin Agro Raya Tbk JARR | 1,845 IDR | 610.80 IDR | -67% |
Compare Humanoid, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Humanoid, Inc (HERB) overvalued or undervalued?
What is the fair value of HERB?
What is the quality score of HERB?
What is the revenue of Humanoid, Inc (HERB)?
What is the net profit margin of HERB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Humanoid, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.